All In Biotech

Drug Trial Radar · NCT07392866

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

A Prospective, Randomized, Active-Controlled, Open-Label, National Multicenter Phase II/III Registration Study of SH006 Injection Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Mar 1, 2030

Study completion Mar 1, 2030

Sponsor

Sponsor type
Industry
First posted
Feb 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of the combination therapy of SH006 injection in the treatment of advanced hepatocellular carcinoma

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

  • SH006Drug

    15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

  • BevacizumabDrug

    15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

  • Oxaliplatin injectionDrug

    85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle

  • CapecitabineDrug

    1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle

  • RegorafenibDrug

    160 mg orally once daily for 21 days continuous dosing followed by a 7-day break of each 28-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) (Phase II)Time frame: Up to approximately 4 years
  2. Incidence of Adverse Events (AEs) (Phase II)Time frame: Up to approximately 4 years
  3. Overall Survival (OS) (Phase III)Time frame: Up to approximately 4 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Nanjing Tianyinshan Hospital

    Nanjing, Jiangsu, China

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.